Literature DB >> 22244728

Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer.

James N George1, Deirdra R Terrell, Sara K Vesely, Johanna A Kremer Hovinga, Bernhard Lämmle.   

Abstract

Thrombotic microangiopathy (TMA) has multiple etiologies. In the four disorders described in this review, the primary organ involved is the kidney. Drug-associated TMA can be an acute, immune-mediated disorder or the result of gradual, dose-dependent toxicity. TMA may occur in patients with advanced HIV infection, possibly mediated by angio-invasive infections. TMA following allogeneic hematopoietic stem cell transplantation may also be caused by drug toxicity; the pathogenesis may involve inhibition of vascular endothelial cell growth factor in renal podocytes. Malignancies of many types with systemic microvascular involvement may cause TMA. Recognition that these syndromes may mimic TTP is important to provide appropriate management and to avoid the inappropriate use of plasma exchange treatment. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22244728     DOI: 10.1016/j.lpm.2011.10.026

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  10 in total

1.  Microangiopathy is common in submucosal vessels of the colon in patients with diabetes mellitus.

Authors:  Agata Sasor; Bodil Ohlsson
Journal:  Rev Diabet Stud       Date:  2014-08-10

Review 2.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

3.  Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Jiaqian Qi; Jie Wang; Jia Chen; Jian Su; Yaqiong Tang; Xiaojin Wu; Xiao Ma; Feng Chen; Changgeng Ruan; X Long Zheng; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2017-08-11       Impact factor: 3.673

4.  Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome.

Authors:  Jonatan Leffler; Zoltán Prohászka; Bálint Mikes; György Sinkovits; Katarzyna Ciacma; Péter Farkas; Marienn Réti; Kata Kelen; György S Reusz; Attila J Szabó; Myriam Martin; Anna M Blom
Journal:  J Innate Immun       Date:  2016-10-27       Impact factor: 7.349

Review 5.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

6.  Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.

Authors:  Aaysha Kapila; Lovely Chhabra; Vinod K Chaubey; Jeffery Summers
Journal:  BMJ Case Rep       Date:  2014-03-03

7.  Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.

Authors:  Julien Mahe; Aurélie Meurette; Anne Moreau; Caroline Vercel; Pascale Jolliet
Journal:  Drug Des Devel Ther       Date:  2013-08-07       Impact factor: 4.162

Review 8.  Atypical Hemolytic Uremic Syndrome: A Brief Review.

Authors:  Kuixing Zhang; Yuxin Lu; Kevin T Harley; Minh-Ha Tran
Journal:  Hematol Rep       Date:  2017-06-01

Review 9.  Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat.

Authors:  Masashi Mizuno; Yasuhiko Ito; B Paul Morgan
Journal:  Mar Drugs       Date:  2012-07-23       Impact factor: 6.085

10.  Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-01-11       Impact factor: 17.586

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.